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Bloom’s syndrome (BS) is an autosomal recessive disorder associ-
ated with dwarfism, immunodeficiency, reduced fertility, and el-
evated levels of many types of cancer. BS cells show marked
genomic instability; in particular, hyperrecombination between
sister chromatids and homologous chromosomes. This instability is
thought to result from defective processing of DNA replication
intermediates. The gene mutated in BS, BLM, encodes a member of
the RecQ family of DExH box DNA helicases, which also includes the
Werner’s syndrome gene product. We have investigated the mech-
anism by which BLM suppresses hyperrecombination. Here, we
show that BLM selectively binds Holliday junctions in vitro and acts
on recombination intermediates containing a Holliday junction to
promote ATP-dependent branch migration. We present a model in
which BLM disrupts potentially recombinogenic molecules that
arise at sites of stalled replication forks. Our results have implica-
tions for the role of BLM as an anti-recombinase in the suppression
of tumorigenesis.
B loom’s syndrome (BS) is an autosomal recessive disorderwith a wide range of symptoms, including immunodefi-
ciency, short stature, subfertility, and a greatly elevated inci-
dence of a broad spectrum of cancers (1, 2). Cells isolated from
BS individuals display a variety of abnormalities, with the
hallmark feature being hyperrecombination between sister-
chromatids and homologous chromosomes. These recombina-
tion events can be visualized cytogenetically as sister-chromatid
exchanges and quadriradial chromosomes. BS cells also display
more general features of genomic instability, such as a mutator
phenotype and an elevated frequency of a variety of chromo-
somal aberrations (1–3).
The gene mutated in BS, BLM, lies on chromosome 15q in
humans (4). Analysis of the BLM cDNA revealed that the
predicted amino acid sequence of the BLM protein shows
significant similarity to the sequences of DNA and RNA heli-
cases (4). Based on these sequence comparisons, and more
latterly on functional studies, BLM has been assigned to the
so-called RecQ family of DNA helicases, named after the
Escherichia coli recQ gene product (reviewed in refs. 5 and 6).
Analysis of recQ mutants has indicated that RecQ protein
participates in homologous recombination, but acts as a sup-
pressor of illegitimate recombination (7, 8). Moreover, in com-
bination with RecA and SSB, RecQ can initiate DNA recom-
bination reactions and disrupt recombination intermediates (9).
Other RecQ family members include Saccharomyces cerevisiae
Sgs1p (10, 11), Schizosaccharomyces pombe Rqh1p (12, 13), and
the RECQL, WRN, RECQ4, and RECQ5 proteins from human
cells (14–17). In vitro studies have shown that many RecQ family
proteins are DNA-dependent ATPases and ATP-dependent
DNA helicases that translocate in the 39–59 direction (5, 6).
BLM is not the only member of the RecQ family of proteins
to be implicated in a human genetic disorder. The WRN gene is
mutated in the premature aging condition Werner’s syndrome
(WS) (16), and the RECQ4 gene is defective in some cases of
Rothmund–Thomson syndrome (RTS) (18), a rare disorder
associated with skin and skeletal abnormalities (19). WS and
RTS are also associated with cancer predisposition, although to
a more limited extent than is seen with BS. Moreover, in
common with BS, cells derived from WS and RTS individuals
show genomic instability (19, 20).
The primary defect leading to hyperrecombination in BS cells
is thought to be a delay in the maturation of certain DNA
replication intermediates (21, 22). One possible role for BLM
would be to prevent DNA structures that arise at blocked or
collapsed replication forks from being processed into mature
recombinants (5, 6). Here, we have investigated one mechanism
by which BLM could suppress hyperrecombination in human
cells. We show that BLM possesses the ability to selectively
recognize Holliday junctions in vitro. Moreover, we show that
BLM efficiently promotes ATP-dependent branch migration of
Holliday junctions through greater than 2 kb of DNA.
Materials and Methods
Proteins. Recombinant human BLM, E. coli RuvA, RuvB, and
RecA were purified as described previously (23–26). PcrA was a
gift from D. Wigley (University of Oxford, Oxford, U.K.).
Terminal deoxynucleotidyltransferase, Klenow polymerase, T4
polynucleotide kinase, and restriction enzymes were obtained
from commercial suppliers. Protein concentrations are indicated
in moles of monomer.
DNA Substrates. The synthetic four-way junction (X12) was







GGCAGCGTC) as described (27, 28). X12-1 was 59-32P-labeled
before annealing. Linear single-stranded (ss)DNA and blunt-
ended double-stranded (ds)DNA were made from oligonucleo-
tides BL3 (59-AAAATGAGAAAATTCGACCTATCCTT-
GCGCAGCTCGAGAAGCTCTTACTTTG) or BL3 annealed
to BL4 (59-CAAAGTAAGAGCTTCTCGAGCTGCGCAAG-
GATAGGTCGAATTTTCTCATTTT). The linear duplex used
in Fig. 3 was prepared by annealing X12-1 with its complement
(59-CGGGTCAACGTGGGCAAAGATGTCCTAGCAAG-
CCAGAATTCGGCAGCGTC). A 39-tailed substrate was gen-
erated by annealing oligonucleotides X12-1 and 39-Tail
(59-ATGTCCTAGCAATGTAATCGTCTATGACGTC-39).
pAKE-4 M (4674 bp) was derived from pAKE-7Z (26), and
contains a new NheI site created after fill-in by Klenow enzyme
of the HindIII site in the polylinker. pAKE-4 M was linearized
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with PstI and 39-32P-end-labeled with terminal transferase and
[a-32P]ddATP. Gapped duplex pDEA-7Z DNA was prepared as
described (26). The 488-bp linear duplex was produced by
digestion of pYES2 DNA with PstI and 39-32P-end labeled using
terminal transferase. All DNA concentrations are indicated in
moles of substrate.
Branch Migration Assays. a-Structures were prepared by RecA-
mediated strand-exchange, then deproteinized and purified as
described (26). Reactions (15 ml) for BLM-mediated branch
migration contained 32P-labeled recombination intermediates
(0.13 nM) in 20 mM TriszHCl, pH 7.5, 1.25 mM MgCl2, 2 mM
ATP, 0.1 mgyml BSA, and 1 mM DTT. PcrA reactions were
carried out in 20 mM TriszHCl, pH 7.5, 3 mM MgCl2, 100 mM
NaCl, 10% glycerol, 2 mM ATP, 0.1 mgyml BSA, and 5 mM
DTT. RuvAB reactions contained RuvA (40 nM) and RuvB (20
nM) in 20 mM TriszHCl, pH 7.5, 15 mM MgCl2, 2 mM ATP, 0.1
mgyml BSA, and 1 mM DTT. After 45 min at 37°C, reactions
were stopped, deproteinized, and 32P-labeled products were
visualized by electrophoresis through 1% agarose gels and
autoradiography. Gels were run in TAE buffer containing 0.5
mgyml ethidium bromide (26).
Band-Shift Assays. Proteins and DNA were incubated in 20 mM
triethanolaminezHCl, pH 7.5, 2 mM MgCl2, 1 mM adenosine
59-[g-thio]triphosphate (ATPgS), 0.1 mgyml BSA, and 1 mM
DTT at room temperature for 20 min. Protein-DNA complexes
were fixed with glutaraldehyde (29) and visualized by autoradiog-
raphy after PAGE through a 5% gel.
X-Junction Dissociation Assays. Proteins and DNA were incubated
in 50 mM TriszHCl, pH 7.5, 2 mM MgCl2, 2 mM ATP, and 0.1
mgyml BSA. After incubation at 37°C, samples were separated
on 10% nondenaturing PAGE gels. Products were visualized by
autoradiography.
Results and Discussion
BLM Promotes Branch Migration of Holliday Junctions. Cells from BS
individuals show elevated levels of recombination between sister
chromatids and homologous chromosomes, suggesting that BLM
is required for the prevention of homologous recombination
events (1, 2, 30). For example, BLM might disrupt Holliday
junctions, preventing their subsequent processing into recombi-
nant products. To address this possibility, we investigated
whether BLM could interact with recombination intermediates
Fig. 1. Branch migration of recombination intermediates catalyzed by BLM.
(a) Schematic diagram indicating the formation of recombination intermedi-
ates (a-structures) by RecA and BLM-mediated branch migration back to the
starting substrates. *, 32P labels. (b) Recombination intermediates were incu-
bated with BLM, RuvAB, or PcrA as indicated, and the 32P-labeled products
were analyzed as described in Methods. The linear duplex product of branch
migration (L) is indicated. (c) Time course showing that BLM (20 nM) is unable
to unwind a 488-bp linear duplex (1 nM).
Fig. 2. Effect of ATP and RuvA on BLM-mediated branch migration. Reac-
tions were carried out as described in Fig. 1. (a) Time courses were conducted
in standard buffer (containing ATP), or in buffer from which ATP was omitted
or replaced with 2 mM adenosine 59-[b,g-imido]triphosphate (AMP-PNP). (b)
The formation of 32P-labeled branch migration products in a was quantified by
phosphorimaging and expressed as a percentage of total radiolabel. (c)
Recombination intermediates were preincubated with or without RuvA, as
indicated, for 3 min on ice. BLM (18 nM) was then added, and reactions were
incubated at 37°C for 45 min. Branch migration products were analyzed as in
Fig. 1.








and promote in vitro branch migration reactions similar to those
mediated by E. coli RuvAB or RecG (31, 32). To do this,
a-structures containing Holliday junctions were prepared by
RecA-mediated DNA strand exchange between gapped circular
and partially homologous 32P-labeled linear duplex DNA (Fig.
1a). Using these substrates, strand exchange proceeds for 2765
bp, but is prevented from reaching completion by the presence
of a 1670-bp region of sequence heterology at the distal end of
the linear DNA. RuvAB and RecG promote branch migration
reactions resulting in the dissociation of the recombination
intermediates, regenerating the starting substrates (gapped cir-
cular and 32P-labeled linear duplex DNA). The formation of the
linear duplex, detected by agarose gel electrophoresis and au-
toradiography, is the signature of branch migration activity. We
found that BLM catalyzed efficient branch migration (Fig. 1b,
lanes b–f) in a manner similar to that promoted by RuvAB (lane
g). The formation of branch migration products depended on
ATP hydrolysis; neither adenosine 59-[b,g-imido]triphosphate
(AMP-PNP) nor adenosine 59-[g-thio]triphosphate (ATPgS)
could substitute for ATP (Fig. 2 a and b, and data not shown).
Control reactions showed that a different DNA helicase (PcrA),
which, like BLM, shows a 39–59 unwinding polarity, but is also
capable of unwinding DNA from blunt ends (23, 33), did not
promote branch migration (Fig. 1b, lanes h–k). We confirmed
that PcrA was active in standard DNA-unwinding assays (data
not shown). Consistent with a specific interaction of BLM with
the Holliday junction leading to branch migration over an
extended length of DNA (.2.5 kb), BLM was unable to catalyze
conventional unwinding of a far smaller (488 bp) 39-tailed
restriction fragment under the same reaction conditions (Fig.
1c). Indeed, in work to be published elsewhere (Brosh et al.,
unpublished observations), it has been shown that, in the ab-
sence of a ssDNA binding protein, BLM is incapable of unwind-
ing 39 tailed substrates of approximately 250 bp.
Specificity of the BLM–Holliday Junction Interaction. The motor of
branch migration in E. coli, RuvB, is relatively inefficient at
promoting Holliday junction branch migration, but is stimulated
by an association with RuvA, which serves to target RuvB to the
junction by virtue of its junction-specific binding activity (28, 31,
34). We found that a short preincubation of the a-structure with
RuvA prevented BLM-catalyzed branch migration, indicating
that BLM interacts with the Holliday junction to promote branch
migration (Fig. 2c, lanes b–e). Hence, we next used band-shift
assays to determine whether BLM interacts directly with Hol-
liday junctions. Using 32P-labeled synthetic four-way junctions
(X-junctions) that model Holliday junctions, we found that BLM
bound X-junction DNA in a protein concentration-dependent
manner (Fig. 3, lanes a–e). To assess whether BLM was recog-
nizing the duplex arms of the X-junction, the blunt-ended
termini of the arms, or the crossover itself, we analyzed whether
BLM could bind under the same band-shift assay conditions to
blunt-ended, linear duplex DNA. BLM failed to form a stable
complex with linear duplex DNA with a sequence identical to
that of one of the ‘‘arms’’ of the X-junction as well as to a similar
DNA molecule of unrelated sequence (Fig. 3, lanes p–t; and data
not shown), indicating that BLM specifically interacts with the
crossover present in the synthetic Holliday junction. Next, we
studied the relative efficiency with which BLM binds X-junction
DNA, a 39-tailed duplex (a standard substrate used for analysis
of DNA unwinding by 39–59 DNA helicases such as BLM) and
ssDNA. BLM formed a specific complex with each of these DNA
molecules (Fig. 3, lanes a–e, f–j, and k–o, respectively). On the
basis of averaging the results of three independent experiments,
the level of complex formation at an equivalent BLM concen-
tration was approximately 2- and 5-fold higher with the X-junc-
tion DNA than with 39-tailed DNA and ssDNA, respectively.
That BLM interacts selectively with Holliday junctions was
supported by observations showing that unlabeled X-junctions
(Fig. 4a, lanes b–g), but not ssDNA (Fig. 4b, lanes b–g), dsDNA
(Fig. 4c, lanes b–g), or 39-tailed duplex DNA (Fig. 4d, lanes b–g)
acted as an efficient competitor for the binding of BLM to
X-junctions. On the basis of averaging the results of three to five
independent experiments in each case, the concentration of
competitor required to reduce binding of BLM to the X-junction
DNA to 50% of control values was as follows: X-junction, 7.6
mM; ssDNA, .100 mM; dsDNA, .100 mM; 39-tailed DNA, 46.8
mM. Hence, based on these analyses, it would appear that BLM
Fig. 3. BLM binds selectively to synthetic X-junctions. Band-shift assays were carried out as described in Methods using 0.5 nM substrate representing either
32P-labeled X-junction (lanes a–e), 39-tailed duplex DNA (lanes f–j), ssDNA (lanes k–o), or blunt-ended dsDNA (lanes p–t), together with the indicated
concentrations of BLM.
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shows an affinity for X-junction DNA that is .15-fold higher
than for ssDNA or dsDNA, and approximately 6-fold higher
than for 39-tailed DNA. Consistent with the notion that BLM
recognizes the DNA crossover, the RuvA protein was found to
compete efficiently with BLM for binding to the X-junction (Fig.
4e, lanes b–g; ,3 mM RuvA required to reduce BLM binding by
50%). Analysis of this competition indicated that the affinity of
BLM for the junction was less than that observed with RuvA,
because, in the presence of a 5-fold excess of BLM over RuvA
(based on moles of monomer), RuvA-junction complexes pre-
dominated (Fig. 4e, lane d).
In addition to dissociating recombination intermediates made
by RecA (Figs. 1 and 2), we also observed that BLM could
promote ATP-dependent dissociation of 32P-labeled synthetic
X-junctions in vitro. BLM-mediated junction dissociation was
found to be blocked by the presence of unlabeled X-junction
competitor, but not by 39-tailed DNA, ssDNA, or dsDNA (data
not shown). Moreover, the RuvA protein also efficiently blocked
junction dissociation. These data support the notion that BLM
exhibits some specificity for Holliday junctions in duplex DNA.
Interestingly, recent studies have shown that BLM (24), like
the RuvB branch migration motor (35), forms oligomeric ring
structures, despite the absence of extensive primary sequence
similarity between the proteins. Further work will be required to
reveal whether BLM and RuvB recognize Holliday junctions and
catalyze branch migration in a mechanistically similar manner.
A Model for the Role of BLM as a Suppressor of Recombination.
Several lines of evidence indicate that BLM and other members
of the RecQ helicase family act during DNA replication; in
particular, BS cells show retarded S-phase progression and an
accumulation of abnormal replication intermediates (21, 22).
Moreover, the high levels of sister-chromatid exchanges that are
the hallmark of BS cells occur primarily as a result of replication
proceeding on a template that has incorporated bromodeoxyuri-
dine, which is used to reveal the exchanges cytogenetically (36).
These data, combined with evidence that BLM serves to prevent
‘‘promiscuous’’ homologous recombination, lead us to propose
the model presented in Fig. 5. In this model, BLM acts at sites
of stalled or disrupted replication forks to prevent inadvertent or
promiscuous recombination. The free DNA ends of the newly
synthesized daughter strands at a stalled replication fork may
anneal to each other, forming a Holliday junction, as suggested
previously from studies of E. coli ruvABC mutants (37). We
propose that BLM recognizes the Holliday junction and cata-
lyzes reverse branch migration, leading to the restoration of the
replication fork. In this way, the induction of dsDNA breaks,
through the action of an as yet unidentified Holliday junction
resolvase (equivalent to E. coli RuvC) (38), is minimized. On
removal of the blockade, replication can recommence. In the
absence of BLM, in BS cells, Holliday junctions are likely to
persist during S-phase at sites of stalled forks, allowing junction-
resolution to occur, leading to the initiation of double-strand
Fig. 4. Competition for binding of BLM to the X-junction. Band-shift assays
were carried out using BLM (68 nM) and 32P-labeled X-junction (0.5 nM) as
described in Methods. (a) Unlabeled X-junction competitor; (b) ssDNA com-
petitor; (c) dsDNA competitor; (d) 39-tailed duplex competitor; (e) RuvA com-
petitor. Lanes: a, no competitor; b, 3.1 nM; c, 6.3 nM; d, 12.5 nM; e, 25 nM; f,
50 nM; g, 100 nM competitor in each case. Fig. 5. Model for the role of BLM as an anti-recombinase at sites of blocked
replication forks. At sites of stalled forks (a), nascent DNA strands can disso-
ciate from the template and anneal to each other, generating a Holliday
junction (b). If this structure is not destroyed by the reverse branch migration
activity of BLM, as indicated, junction resolution can occur (c) with the gen-
eration of a dsDNA break (d) and the subsequent formation of recombinants.
See text for details.








break repair by homologous recombination. Because RecQ and
Sgs1 can disrupt synthetic 3- and 4-way junctions in vitro (9, 39),
it is possible that the promotion of Holliday junction branch
migration is a universal property of RecQ family helicases.
Further work will be required to confirm this.
A question that arises from this model is how directionality
might be imposed on the branch migration reaction, because
there would be a requirement for branch migration to proceed
in a reverse direction in order for the junction to be dissociated,
as has been shown previously for RecG (32). Forward branch
migration would cause the junction to translocate away from the
point where replication fork progression was halted. For BLM to
act in a directional manner would likely require the participation
of other factors to effect the asymmetric binding of BLM to the
junction. For example, proteins that are already associated with
the fork might impose a bias in how BLM binds junctions. It may
be significant in this regard that functional interactions have
been identified between BLM and replication protein A, the
ssDNA binding protein (Brosh et al., unpublished observations).
Our model has similarities to and differences from the model
proposed recently by Courcelle and Hanawalt (40). In their
model, based on an analysis of E. coli recQ mutants, it was
proposed that the RecQ helicase in conjunction with RecJ
nuclease selectively degrade the nascent lagging strand at
blocked replication forks both to prevent illegitimate recombi-
nation and to stabilize the fork to ensure that accurate recovery
of replication can occur when the blockade has been removed.
In our model for the action of BLM in human cells, BLM
achieves a similar goal—that of preventing ‘‘promiscuous’’ re-
combination events and stabilization of the fork—but by the
route of eliminating a Holliday junction recombination inter-
mediate. Given that there are at least five members of the RecQ
family in human cells, it is conceivable that a family member
other than BLM is involved in a degradative reaction analogous
to that proposed for RecQyRecJ. It may be significant in this
regard that the WRN protein is a combined helicaseynuclease
(41, 42).
It should be noted that, whereas BLM promotes efficient
disruption of recombination intermediates, it clearly is not
limited to this role. Previous work has shown that BLM is a
general helicase with preference for G-quadruplex DNA (43).
Hence, BLM may play at least two roles in the cell: one
concerned with Holliday junction interactions, and the other
concerned with disruption of DNA secondary structures that
impede the progress of protein complexes involved in replication
andyor recombination.
In summary, we have shown that the BS gene product can
promote branch migration. We suggest that the anti-
recombinase role of BLM is important to maintain genome
stability and is critical in suppressing tumorigenesis in humans.
In future studies, it will be interesting to determine whether
WRN and RECQ4, the RecQ family helicases defective in
Werner’s and Rothmund–Thomson syndromes (16, 18), display
similar anti-recombinase activities.
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